Should I buy Dexcom (DXCM) stock or is it too late?

Dexcom · Health Care · price $85

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: JP Morgan — 68% of its targets hit on this sector (364 calls tested). It aims for $82 (-3.6 %), call made on August 1, 2026, maturing on August 1, 2027 (74 d ago).

The 13 reliable analysts $95+12 %

The 3 other firms $86+1.1 %

How to read it: the 13 reliable firms are not filtered by optimism — 11 aim above the price, 2 below, hence their $95 median. “The 3 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Dexcom

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
B of A Securities	100 %	+59.1 %	6	$80 -6%
JP Morgan	92 %	+53.0 %	12	$82 -4%
Canaccord Genuity	71 %	+36.0 %	24	$90 +6%
Stifel	73 %	+32.0 %	11	$95 +12%
Raymond James	63 %	+24.4 %	30	$102 +20%
BTIG	67 %	+7.0 %	9	$96 +13%
Piper Sandler	59 %	+5.3 %	17	$95 +12%
Citigroup	58 %	+0.3 %	12	$88 +3%

In short — Should you invest in Dexcom? Is it too late, still worth it? Analysts are overwhelmingly positive (94% buy, median target $95, i.e. +12%). But the valuation is stretched (P/E ~34), it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

94% of analysts rate it a buy (Buy consensus, 16 ratings) — a sign of market conviction.
Median price target $95, i.e. +12% from the current price ($85).
10 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.

⚠️ Reasons to hesitate

Even the most reliable firm on DXCM, B of A Securities (100% hit rate, 6 scored calls), only targets $80 (call made on May 18, 2026, maturing on May 18, 2027) (-6%) in its most recent call. The stock may already have run past its target.
The consensus is not unanimous: of 16 ratings, 1 is neutral.
High valuation (P/E ~34): strong growth is already "priced in", leaving little room for error.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on DXCM

Median target $95 (+12%) · 16 ratings · Buy consensus

Strong Buy00%

Buy1594%

Hold16%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Dexcom now?

We won't decide for you. The facts: 94% of analysts rate it a buy, median target $95 (+12%), and B of A Securities (most reliable on DXCM, 100%) targets $80. Weigh that against valuation (P/E ~34). This is not personalized advice.

Is it too late to invest in Dexcom?

Not according to analysts: the median target ($95) is still +12% above the current price ($85) (most reliable on DXCM: B of A Securities, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Dexcom still worth investing in?

It depends on the gap between the price ($85) and its estimated value: analysts target $95 on median (+12%), with 94% buys (most reliable on DXCM: B of A Securities, 100%). Cross-check with their real reliability on DXCM and the cautions above. Information, not advice.

What's the main risk in buying DXCM?

Even the most reliable firm on DXCM, B of A Securities (100% hit rate, 6 scored calls), only targets $80 (call made on May 18, 2026, maturing on May 18, 2027) (-6%) in its most recent call. The stock may already have run past its target.

→ Go deeper: the full Dexcom profile (consensus, analyst reliability, price target, performance).